GlassScriptPhysician profile
Nicole Lorang
NPI 1295110385
$18,679.34
in general payments reported to CMS, 2019-2025
52 companies · $5,158 in 2025
The $5,158 reported for 2025 was more than what 99% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,397 · 2022: $2,945 · 2023: $3,994 · 2024: $4,185 · 2025: $5,158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $49.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,287.07 |
| Education | $49.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $2,934.65 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $2,870.29 | 2021-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $1,356.41 | 2021-2025 | Korlym |
| Novo Nordisk INC | $1,102.52 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amneal Pharmaceuticals LLC | $738.33 | 2021-2025 | Unithroid |
| Amgen INC. | $671.60 | 2021-2025 | Evenity, Prolia, Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $659.73 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Mannkind Corporation | $627.19 | 2021-2025 | Afrezza |
| Sanofi-Aventis U.S. LLC | $532.87 | 2021-2024 | |
| Abbott Laboratories | $508.39 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Bayer Healthcare Pharmaceuticals INC. | $505.09 | 2022-2025 | |
| Antares Pharma, INC. | $478.93 | 2021-2025 | Xyosted, Nocdurna, Tlando |
| Xeris Pharmaceuticals, INC. | $455.15 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Tandem Diabetes Care, INC. | $435.91 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ascensia Diabetes Care US INC. | $423.04 | 2021-2025 |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $365.93 | 2021-2025 | Nexletol |
| Abbvie INC. | $334.42 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $312.71 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $272.75 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $266.55 | 2021-2025 | Strensiq |
| Recordati_rare_diseases_inc. | $239.01 | 2023-2025 | Isturisa, Signifor Lar |
| Ibsa Pharma INC. | $237.62 | 2021-2025 | Tirosint, Tirosint, Licart |
| Ascendis Pharma Endocrinology INC | $231.27 | 2024-2025 | Yorvipath |
| Radius Health, INC. | $205.05 | 2023-2025 | Tymlos |
| Beta Bionics, INC. | $197.00 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Merck Sharp & Dohme LLC | $173.77 | 2021-2023 | Steglatro |
| Madrigal Pharmaceuticals | $169.26 | 2025 | Rezdiffra |
| Astrazeneca Pharmaceuticals LP | $164.37 | 2021-2023 | Farxiga |
| Insulet Corporation | $132.17 | 2025 | Omnipod |
| Astellas Pharma US INC | $114.93 | 2023-2025 | Veozah |
| Amarin Pharma, INC. | $110.16 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $88.96 | 2021-2023 | |
| Medtronic, INC. | $86.09 | 2024-2025 | Minimed 780g, Intellis Adaptivestim |
| Cequr Corporation | $81.62 | 2023-2024 | Cequr Simplicity |
| Halozyme INC | $61.26 | 2023 | |
| Amphastar Pharmaceuticals, INC. | $59.84 | 2024-2025 | |
| Rhythm Pharmaceuticals, INC. | $55.09 | 2022-2025 | Imcivree |
| Embecta Corp. | $49.86 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Opko Pharmaceuticals, LLC | $37.45 | 2023 | Rayaldee |
| Clarus Therapeutics INC. | $35.56 | 2021 | |
| Amryt Pharma Holdings LTD | $35.46 | 2023 | Mycapssa |
| Vivus LLC | $34.51 | 2022-2025 | Qsymia |
| Acella Pharmaceuticals, LLC | $34.32 | 2023-2025 | NP Thyroid 60 |
| Glaxosmithkline, LLC. | $31.49 | 2025 | Shingrix, Arexvy |
| Organogenesis INC. | $28.94 | 2021 | |
| Kyowa Kirin, INC. | $25.24 | 2023 | |
| Nevro Corp. | $22.15 | 2024 | Senza |
| Chiesi USA, INC. | $21.68 | 2025 | Mycapssa |
| Zealand Pharma US, INC. | $20.04 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $15.53 | 2021 | |
| Lifescan, INC. | $15.20 | 2021 | |
| Theracosbio, LLC | $11.98 | 2024 | Brenzavvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Lorang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.